Rokaya El Ansari
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
El Ansari, Rokaya; Craze, Madeleine L.; Miligy, Islam; Diez-Rodriguez, Maria; Nolan, Christopher C.; Ellis, Ian O.; Rakha, Emad; Green, Andrew R.
Authors
Madeleine L. Craze
Islam Miligy
Maria Diez-Rodriguez
Christopher C. Nolan
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Abstract
Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology and patient outcome. The amino acid transporter, SLC7A5, plays a role in BC although its impact on patient outcome in different BC subtypes remains to be validated. This study aimed to determine whether the clinicopathological and prognostic value of SLC7A5 is different within the molecular classes of BC.
Methods: SLC7A5 was assessed at the genomic, using METABRIC data (n=1,980), and proteomic, using immunohistochemistry and TMA (n= 2664; 1,110 training and 1,554 validation sets), levels in well-characterised primary BC cohorts. SLC7A5 expression was correlated with clinicopathological and biological parameters, molecular subtypes, and patient outcome.
Results: SLC7A5 mRNA and protein expression were strongly correlated with larger tumour size, and higher grade. High expression was observed in triple negative (TN), HER2+, and luminal B subtypes. SLC7A5 mRNA and protein expression was significantly associated with the expression of the key regulator of tumour cell metabolism c-MYC, specifically in Luminal B tumours only (p=0.001). High expression of SLC7A5 mRNA and protein was associated with poor patient outcome (p
Citation
El Ansari, R., Craze, M. L., Miligy, I., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., …Green, A. R. (in press). The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research, 20(21), https://doi.org/10.1186/s13058-018-0946-6
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 26, 2018 |
Online Publication Date | Mar 22, 2018 |
Deposit Date | Feb 23, 2018 |
Publicly Available Date | Mar 29, 2024 |
Journal | Breast Cancer Research |
Print ISSN | 1465-5411 |
Electronic ISSN | 1465-542X |
Publisher | Springer Verlag |
Peer Reviewed | Peer Reviewed |
Volume | 20 |
Issue | 21 |
DOI | https://doi.org/10.1186/s13058-018-0946-6 |
Keywords | SLC7A5; breast cancer; prognosis |
Public URL | https://nottingham-repository.worktribe.com/output/921060 |
Publisher URL | https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0946-6 |
Files
s13058-018-0946-6.pdf
(2 Mb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
Related Outputs
Glutamate dehydrogenase (GLUD1) expression in breast cancer
(2018)
Journal Article
MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer
(2017)
Journal Article
You might also like
Glutamate dehydrogenase (GLUD1) expression in breast cancer
(2018)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search